for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Celgene Corporation

CELG.O

Latest Trade

98.60USD

Change

0.22(+0.22%)

Volume

3,110,545

Today's Range

98.26

 - 

98.99

52 Week Range

58.59

 - 

99.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
98.38
Open
98.26
Volume
3,110,545
3M AVG Volume
81.36
Today's High
98.99
Today's Low
98.26
52 Week High
99.36
52 Week Low
58.59
Shares Out (MIL)
708.74
Market Cap (MIL)
69,725.97
Forward P/E
9.09
Dividend (Yield %)
--

Next Event

Q3 2019 Celgene Corp Earnings Release

Latest Developments

More

Celgene's Cc-486 Tested As Maintenance Therapy For AML Succeeds In Phase 3 Study

U.S. FDA Approves Inrebic As First New Treatment In Nearly A Decade For Patients With Myelofibrosis

FDA Says Granted Approval Of Inrebic To Impact Biomedicines, A Unit Of Celgene Corporation

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Industry

Biotechnology & Drugs

Contact Info

86 Morris Ave

+1.908.6739000

http://www.celgene.com/

Executive Leadership

Mark J. Alles

Chairman of the Board, Chief Executive Officer

Alise S. Reicin

President - Global Clinical Development

David V. Elkins

Chief Financial Officer, Executive Vice President

Terrie Curran

President, Global Inflammation & Immunology Franchise

Rupert J. Vessey

President - Research and Early Development

Key Stats

2.84 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

11.2K

2017

13.0K

2018

15.3K

2019(E)

17.4K
EPS (USD)

2016

5.940

2017

7.440

2018

8.870

2019(E)

10.818
Price To Earnings (TTM)
13.57
Price To Sales (TTM)
4.26
Price To Book (MRQ)
6.93
Price To Cash Flow (TTM)
11.85
Total Debt To Equity (MRQ)
196.90
LT Debt To Equity (MRQ)
196.90
Return on Investment (TTM)
16.23
Return on Equity (TTM)
14.40

Latest News

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion

Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash

Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.

FDA approves Celgene's bone marrow cancer treatment

The U.S. Food and Drug Administration on Friday approved Celgene Corp's Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved drug to treat the disease.

REFILE-FDA approves Celgene's bone marrow cancer treatment

The U.S. Food and Drug Administration said on Friday it had approved Celgene Corp's treatment, Inrebic, for certain forms of bone marrow cancer.

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

Bristol-Myers says shareholders vote to approve Celgene takeover

Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Bristol-Myers says shareholders vote to approve Celgene takeover

Bristol-Myers Squibb Inc's shareholders voted to approve the drugmaker's $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

Starboard no longer urging investors to vote against Bristol-Celgene deal

Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

UPDATE 1-Starboard no longer urging investors to vote against Bristol-Celgene deal

Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

Starboard no longer urging investors to vote against Bristol-Celgene deal

Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

REFILE-Proxy advisor ISS backs Bristol takeover of Celgene

Proxy advisory firm Institutional Shareholder Services on Friday recommended shareholders of drugmaker Bristol-Myers Squibb Co shareholders vote in favor of its proposed $74 billion takeover of rival Celgene Corp.

FTC focuses on psoriasis franchise for Bristol-Celgene deal review

The U.S. Federal Trade Commission has sought additional information from Bristol-Myers Squibb Co and Celgene Corp and is focusing on the companies' psoriasis treatments as part of its review of their planned merger, Bristol-Myers said on Tuesday.

FTC seeks more information to review Bristol-Celgene's $74 bln planned merger

The U.S. Federal Trade Commission has sought additional information and documents from Bristol-Myers Squibb Co and Celgene Corp in connection with its review of their planned merger, Bristol-Myers said on Tuesday.

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.

UPDATE 1-U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.

Third Point holds Celgene stock, in bet Bristol-Myers deal will close: source

Daniel Loeb's hedge fund Third Point LLC owns a small stake in Celgene Corp, betting that the proposed $74 billion sale of the biotechnology company to Bristol-Myers Squibb Co will be completed, a person familiar with the matter said on Monday.

Bristol-Myers defends Celgene bet as investor criticism grows

Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, saying it had carried out a "robust" assessment of the merger after two major investors opposed what could be the largest pharmaceutical deal ever.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up